| Title: | CD56-positive diffuse large B-cell lymphoma : comprehensive analysis of clinical, pathological, and molecular characteristics with literature review |
|---|
| Authors: | ID Gašljević, Gorana (Author)
ID Boltežar, Lučka (Author)
ID Novaković, Srdjan (Author)
ID Šetrajčič Dragoš, Vita (Author)
ID Jezeršek Novaković, Barbara (Author)
ID Kloboves-Prevodnik, Veronika (Author) |
|---|
| Files: |  PDF - Presentation file, download (680,06 KB)
MD5: 78F2BF14295E33140E3AA7E2AC340883
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  OI - Institute of Oncology
|
|---|
| Abstract: | Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. The expression of CD56 in DLBCL is highly unusual. Little is known about its incidence and clinical importance. So far, no genetic profiling was performed in CD56 positive DLBCL.Patients and methods. Tissue microarrays have been constructed, sectioned, and stained by H&E and immuno-histochemistry for 229 patients with DLBCL diagnosed 2008–2017. For CD56 positive cases, clinical data was collected including age at diagnosis, stage of the disease, International Prognostic Index (IPI) score, treatment scheme and number of chemotherapy cycles, radiation therapy, treatment outcome, and possible relapse of the disease. Overall survival (OS) and progression-free survival (PFS) were calculated. For four patients, RNA was extracted and targeted RNA (cDNA) sequencing of 125 genes was performed with the Archer FusionPlex Lymphoma kit.Results. CD56 expression was found in 7 cases (3%). The intensity of expression varied from weak to moderate focal, to very intensive and diffuse. All patients had de novo DLBCL. The median age at the time of diagnosis was 54.5 years. Five of them were women and 2 males. According to the Hans algorithm, 6 patients had the germinal centre B cells (GBC) type and one non-GBC (activated B-cell [ABC]) type, double expressor. Genetic profiling of four patients ac-cording to Schmitz’s classification showed that 1 case was of the BN2 subtype, 1 of EZB subtype, 2 were unclassified. The six treated patients reached a complete response and did not experience progression of the disease during the median follow-up period of 80.5 months.Conclusions. We report on one of the largest series of CD56+DLBCL with detailed clinicopathological data and for the first time described genetical findings in a limited number of patients. Our results show that CD56 expression is rare, but seems to be present in prognostic favourable subtypes of DLBCL not otherwise specified (NOS) as tested by immunohistochemical or genetic profiling |
|---|
| Keywords: | diffuse large B-cell lymphoma, immunohistochemistry, lymphomas, CD56 |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Publication date: | 01.06.2023 |
|---|
| Publisher: | Association of Radiology and Oncology |
|---|
| Year of publishing: | 2023 |
|---|
| Number of pages: | str. 249-256 |
|---|
| Numbering: | Vol. 57, no. 2 |
|---|
| Source: | Ljubljana |
|---|
| PID: | 20.500.12556/DiRROS-19829  |
|---|
| UDC: | 616-006.44 |
|---|
| ISSN on article: | 1318-2099 |
|---|
| DOI: | 10.2478/raon-2023-0016 |
|---|
| COBISS.SI-ID: | 147497731 |
|---|
| Copyright: | by Authors |
|---|
| Publication date in DiRROS: | 25.07.2024 |
|---|
| Views: | 16 |
|---|
| Downloads: | 2 |
|---|
| Metadata: |     |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
